“TP53和EGFR扩增是非小细胞肺癌合并脑转移患者总生存率的阴性预测因子”[Heliyon Volume 10, Issue 16, August 2024， Article e36532]的更正。

IF 3.6 3区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Heliyon Pub Date : 2025-05-08 eCollection Date: 2025-05-01 DOI:10.1016/j.heliyon.2025.e43247

Tao Lin, Xusheng Tang, Wanli Yang, Hainan Yang, Zhaoming Zhou, Zhijie Chen, Yongqin Zeng, Weiping Hong, Minting Ye, Linbo Cai, Da Liu, Minying Li, Lei Wen

引用次数: 0

摘要

[这更正了文章DOI: 10.1016/j.h heliyon.2024.e36532.]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Corrigendum to "TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases" [Heliyon Volume 10, Issue 16, August 2024, Article e36532].

[This corrects the article DOI: 10.1016/j.heliyon.2024.e36532.].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Heliyon MULTIDISCIPLINARY SCIENCES-

CiteScore

4.50

自引率

2.50%

发文量

2793

期刊介绍： Heliyon is an all-science, open access journal that is part of the Cell Press family. Any paper reporting scientifically accurate and valuable research, which adheres to accepted ethical and scientific publishing standards, will be considered for publication. Our growing team of dedicated section editors, along with our in-house team, handle your paper and manage the publication process end-to-end, giving your research the editorial support it deserves.